Deepbridge Capital

Microplate Dx develops innovative diagnostic technology aimed at reducing fatalities caused by drug-resistant infections. The company, spun out from the University of Strathclyde in Glasgow, focuses on creating point-of-care solutions that accurately detect specific infections and enable optimal antibiotic prescribing within an hour.

IbisVision Limited is a company that specializes in developing visual field test software aimed at the early detection of glaucoma, a leading cause of blindness. Its flagship product, Ring of Sight, utilizes patented technology to offer a unique eye testing experience through a cloud-based application that can be accessed remotely from various locations. The software consolidates multiple eye tests into one device, allowing healthcare professionals to conduct both in-practice and no-contact testing. This innovative approach not only enhances patient care but also supports optometrists in maximizing operational efficiency. Founded in 2013 and located in Livingston, United Kingdom, IbisVision is committed to improving eye care by providing a reliable and secure platform for diagnosing and monitoring glaucoma. The application ensures data privacy through secure encrypted servers, underscoring the company's dedication to maintaining high standards of patient confidentiality and security.